Tirzepatide Updates & News (March 2025)
The timeframe of early spring 2025 represents a significant point in the development and potential availability of a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist for the management of type 2 diabetes and potentially other metabolic conditions. This dual-action medication offers a promising new approach to glycemic control and weight management….